# Suzhou Yilian Biopharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-yilian-biopharmaceutical-co

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $70M
- Latest round: Series B (Mar 14, 2022)
- Investors on record: 6

## About

Established in 2020 and based in Suzhou, China, Suzhou Yilian Biopharmaceutical Co., Ltd. is a biopharmaceutical company that focuses on research, development and manufacturing next-generation antibody-coupled drugs. The CSO Dr. Jiaqiang Cai has nearly 30 years of experience in small molecule and coupling technology development and has served as Vice President of Shanghai Hansen Pharmaceuticals. The CEO Dr. Tongtong Xue serves as general manager in Kelun Botai. The company has completed 4 rounds of funding as of 2022.

The company's main business is medical research and experimental development, health consulting services ,and research and development of next-generation antibody-coupled drugs. The products used in the field of leukemia, lymphoma, breast cancer and multiple myeloma.

The company plans to use the series A funding to development of next-generation antibody coupled drug (ADC) product pipeline and establishment of novel coupling drug development platform. The company plans to use the series B funding to clinical trial development of next-generation Antibody-Drug Conjugates (ADC) product pipeline, and early stage development of novel coupled drugs.

## Funding rounds

- Series B, Mar 14, 2022, $70M — Legend Capital, Qiming Venture Partners, HighLight Capital, LYFE Capital, Loyal Valley Capital
- Series A, Mar 1, 2021 — Qiming Venture Partners, Loyal Valley Capital, Apricot Capital
- Series A, Jan 1, 2021 — Apricot Capital

## Investors

- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A, Series B
- Legend Capital — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- LYFE Capital — Series B